What If Congress Repealed Obamacare's Individual Mandate?

Life Science Leader Newsletter | February 24, 2015

SPONSOR Chief Medical Officer East This conference is designed specifically for CMOs, but certainly heads of R&D, clinical operations/development/outsourcing, and vice presidents of medical affairs would also greatly benefit from attending the program. Clinical service providers and investors are encouraged to attend, as conversations with CMOs are very much welcomed. Use code LSL15 for 15 percent off registration. Learn more. Featured Articles How To Make Your Science A Sustainable Business By Rob Wright, chief editor, Life Science Leader magazine Jim Robinson, president of Astellas Pharma US, shares business insights to consider when taking your company's drug development dreams from concept to commercial reality and reveals how to avoid letting the allure of science sink your potential product's or company's sustainability. Companies To Watch Roundup 2014 By Wayne Koberstein, executive editor, Life Science Leader magazine We asked each company executive: "What have been the most important developments for your company and what milestones do you anticipate in 2015?" Their stories continue to unfold — blazing new trails, creating new models, and supplying new lessons for life sciences leaders. » Companies To Watch Tetra Discovery Partners By Wayne Koberstein, executive editor, Life Science Leader magazine Tetra revisits a discarded mechanism and finds a new path to broad-based therapeutics for cognition-related diseases such as Alzheimer's. » Capitol Perspectives SGR Offset: Replacing Individual Mandate With Late Enrollment Penalty By John McManus, president and founder, The McManus Group Last year's comprehensive, bipartisan replacement to the sustainable growth rate failed to advance because consensus could not be achieved on whether or how to fund the $120 billion price tag of repealing the pending cuts. Every sector of healthcare would cheer a permanent solution, but it will require collaboration between the Obama administration and Republicans. » Outsourcing Insights The CDMO Model And Outsourcing Development By Kate Hammeke, contributing writer, Life Science Leader magazine Theoretically, the CDMO is positioned for a strategic partnership, with expertise in areas the drug innovator seeks, whereas the CMO may be viewed as a tactical provider that has the available capacity to compete for the project. This perception has influenced many contract manufacturers to embrace the CDMO term as an additional advantage. SPONSOR Research Report: Increased Productivity Through Supply Chain Segmentation In a study conducted by Peerless Research Group (PRG), 140 supply chain executives in manufacturing and warehousing operations offered input on supply chain infrastructures. Specifically, the research examined organizations' adoption of a supply chain segmentation strategy and implementation, and how their approach is delivering enhanced process efficiencies, better inventory management, and improved customer service. This report is an outstanding opportunity for the pharmaceutical industry to capture ideas from a cross section of industry leaders. » Pharma Innovation The New "Era Of Interdependence" By Dennis Purcell, Founder and Senior Advisor, Aisling Capital The life sciences industry is entering a new "Era of Interdependence." The parties involved in bringing a product or service to market are realizing that cooperation is the most productive, cost-efficient route to success. But that has not always been the case. A New In-Depth Analysis Of Global Biosimilar Markets By Fred Olds, contributing writer By the end of this decade, nearly $100 billion of biologics will be exposed to competition due to patent expiration. This tantalizing prospect has led to the formation of an entirely new market — biosimilars. Ireland: A Training Hub For Life Sciences Innovation By Barry Heavey, head of life sciences, IDA Ireland In the last decade, the global life sciences industry has seen tremendous growth, which has necessitated a commensurate growth in its infrastructure, including training centers and R&D facilities. Motivating Improvements In Process Development: The BITE Awards Program At GSK By Chip Reuben, M.S., contributing writer According to S. Joseph Tarnowski, Ph.D., SVP chemistry, manufacturing, and controls Biopharm R&D at GSK, when project teams compete for funding that matters to them, the scientists start to think of new ways to improve pharmaceutical product development. » Editor's Blog A Behind-The-Scenes Look At The 2015 J.P. Morgan Healthcare Conference By Rob Wright, chief editor, Life Science Leader magazine Follow Life Science Leader: